Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -33,887 | -27,947 | -22,816 | -15,938 | -38,243 |
| Depreciation Amortization | 821 | 615 | 409 | 205 | 811 |
| Other Working Capital | -704 | -1,139 | 370 | -715 | -932 |
| Other Operating Activity | 9,190 | 9,180 | 9,071 | 8,874 | 5,292 |
| Operating Cash Flow | $-24,580 | $-19,291 | $-12,966 | $-7,574 | $-33,072 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -104 | N/A | N/A | N/A | -11 |
| Investing Cash Flow | $-104 | $N/A | $N/A | $N/A | $-11 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -10 | -7 | -5 | -2 | -9 |
| Common Stock Issued | N/A | N/A | N/A | N/A | 29,330 |
| Other Financing Activity | -207 | -207 | 0 | 0 | 0 |
| Financing Cash Flow | $-217 | $-214 | $-5 | $-2 | $29,321 |
| Exchange Rate Effect | 6 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 73,228 | 73,228 | 73,228 | 73,228 | 76,990 |
| End Cash Position | 48,333 | 53,723 | 60,257 | 65,652 | 73,228 |
| Net Cash Flow | $-24,895 | $-19,505 | $-12,971 | $-7,576 | $-3,762 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,580 | -19,291 | -12,966 | -7,574 | -33,072 |
| Capital Expenditure | -104 | N/A | N/A | N/A | -11 |
| Free Cash Flow | -24,684 | -19,291 | -12,966 | -7,574 | -33,083 |